Advertisement

Topics

FDA Approves Seattle Genetics' Adcetris to Treat Disfiguring Blood Cancer

19:00 EST 8 Nov 2017 | BioSpace

The approval is based on data from the phase 3 ALCANZA trial and two phase 2 investigator-sponsored trials.

Original Article: FDA Approves Seattle Genetics' Adcetris to Treat Disfiguring Blood Cancer

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Seattle Genetics' Adcetris to Treat Disfiguring Blood Cancer"

Advertisement
Quick Search
Advertisement
Advertisement